The role of rabbit antithymocyte globulin in renal transplantation

Bibliography

• Starzl TE, Marchioro TL, Hutchinson DE. The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation 1967;5(Suppl):1100
   Google Scholar
• UNOS. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients (OPTN/SRTR) 2007 Annual Report. Available from: http:www.optn.org/AR2007/iKI_Recipients_immuno.htm?o=2&g=2&c=19 [Accessed December 2008]
   Google Scholar
• IMTIX-SangStat. Thymoglobuline (rabbit antithymocyte globulin) prescribing information. Lyon: France: 2003
   Google Scholar
• Administration USFaD. Available from: http://www.fda.gov/cber/products/thymoglobulin.htm [Cited 1 August 2008]
   Google Scholar
• Gaber A, First M, Testi R. Results of the double-blinded, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute rejection episodes following renal transplantation. Transplantation 1998;66:29
   PubMed Web of Science ®Google Scholar
• Brennan DC, Flavin K, Lowell JA. A randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011-18
   PubMed Web of Science ®Google Scholar
• Goggins WC, Pascual MA, Powelson JA. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal trnaplant recipients. Transplantation 2003;76:798-802
   PubMed Web of Science ®Google Scholar
• Brennan D, Daller J, Lake K, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-77
   PubMed Web of Science ®Google Scholar
• Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011;364(20):1909-19
   PubMed Web of Science ®Google Scholar
• Zand MS, Thuong V, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79:1507-15
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51:669
   PubMed Web of Science ®Google Scholar
• Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995;59:1194
   PubMed Web of Science ®Google Scholar
• Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994;57:685
   PubMed Web of Science ®Google Scholar
• Preville X, Flacher M, LeMauff B. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001;71:460-8
   PubMed Web of Science ®Google Scholar
• Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal globulins. Blood 1998;91:2360-8
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Genestier L, Preville X, Revillard JP. TNF alpha and CD95-L contribute to apoptosis of activated lymphocytes triggered by ATGs. Transplant Proc 1999;31:775-7
   PubMedGoogle Scholar
• Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy 2006;26(12):1771-83
   PubMed Web of Science ®Google Scholar
• LaCorcia G, Swistak M, Lawendowski C, et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009;87(7):966-74
   PubMedGoogle Scholar
• Popow I, Leitner J, Grabmeier-Pfistershammer K, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transplant 2013;13(12):3103-13
   PubMedGoogle Scholar
• Liu Z, Fang Y, Wang X, et al. Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells. Transplantation 2008;86(10):1419-26
   PubMedGoogle Scholar
• Tang Q, Leung J, Melli K, et al. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int 2012;25(12):1257-67
   PubMed Web of Science ®Google Scholar
• Hardinger K, Schnitzler M, Miller B. Five-year follow up of thymoglobulin versus atgam induction in adult renal transplantation. Transplantation 2004;78:136-41
   PubMed Web of Science ®Google Scholar
• Bouvy AP, Kho MM, Klepper M, et al. Kinetics of homeostatic proliferation and thymopoiesis after rATG induction therapy in kidney transplant patients. Transplantation 2013;96(10):904-13
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Bridous F, Buchler M. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48-56
   PubMed Web of Science ®Google Scholar
• Mourad G, Rostaing L, Legendre C. Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004;78:584-90
   PubMed Web of Science ®Google Scholar
• Knight R, Kerman R, Schoenberg L. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004;78:904-10
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke G, Gaynor J. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005;80:457-65
   PubMed Web of Science ®Google Scholar
• Abou-Ayache R, Buchler M, Lepogamp P, et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids, and delayed cyclosporine A. Nephrol Dial Transplant 2008;23:2024-32
   PubMedGoogle Scholar
• Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009;20(6):1385-92
   PubMed Web of Science ®Google Scholar
• Wolf M, Descourouez JL, Hager DR, Djamali A. Peripheral administration of antithymocyte globulins: a review of current literature. Transplant Rev (Orlando) 2013;27(1):17-20
   PubMedGoogle Scholar
• Agha IA, Rueda J, Alvarez A. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002;73:473-5
   PubMed Web of Science ®Google Scholar
• Wong W, Agrawal N, Pascual M. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006;19:629
   PubMed Web of Science ®Google Scholar
• Gurk-Turner C, Airee R, Philosophe B, Kukuruga D. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008;85:1425-30
   PubMed Web of Science ®Google Scholar
• Tsapepas DS, Mohan S, Tanriover B, et al. Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal. Transplantation 2012;94(4):325-30
   PubMed Web of Science ®Google Scholar
• Hammer C, Thein E. Visualization of the effect of polyclonal antithymocyte globulins on adhesion of leukocytes. Transplant Proc 2002;34:2486
   PubMedGoogle Scholar
• Yokota N, Daniels F, Crosson J. Protective effect of T cell depletion in murine renal iscemia-reperfusion injury. Transplantation 2002;74:759
   PubMedGoogle Scholar
• Peddi V, Bryant M, Roy-Chaudhury P Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002;73:1514-18
   PubMed Web of Science ®Google Scholar
• Pollock-BarZiv SM, Allain-Rooney T, Manlhiot C, et al. Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant recipients; experience and outcomes with a novel strategy for administration. Pediatr Transplant 2009;13(5):585-9
   PubMedGoogle Scholar
• Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008;85(10):1391-9
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Rasu RS, Skelton R, et al. Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? J Transplant 2010;2010:957549
   PubMedGoogle Scholar
• Knight RJ, Villa M, Welsh M. Sirolimus and delayed graft function after renal transplantation [abstract]. Am J Transplant 2003;3(Suppl 5):481
   Google Scholar
• Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008;359:1736-8
   PubMed Web of Science ®Google Scholar
• Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation 2009;87(10):1520-9
   PubMed Web of Science ®Google Scholar
• Hardinger K, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008;86:947-52
   PubMed Web of Science ®Google Scholar
• Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007;83(11):1509-12
   PubMedGoogle Scholar
• Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009;88(6):810-19
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008;22:200-10
   PubMed Web of Science ®Google Scholar
• Hardinger K, Schnitzler M, Koch M. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006;81:1285-9
   PubMed Web of Science ®Google Scholar
• Miller JT, Collins CD, Stuckey LJ, et al. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. Pharmacotherapy 2009;29(10):1166-74
   PubMedGoogle Scholar
• Gaber AO, Matas AJ, Henry ML, et al. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation 2012;94(4):331-7
   PubMedGoogle Scholar
• Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248(4):564-77
   PubMed Web of Science ®Google Scholar
• Woodle ES, Peddi VR, Tomlanovich S, et al. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. Clin Transplant 2010;24(1):73-83
   PubMedGoogle Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-75
   PubMed Web of Science ®Google Scholar
• Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11(8):1633-44
   PubMed Web of Science ®Google Scholar
• Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010;89(12):1511-17
   PubMedGoogle Scholar
• Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007;7(11):2522-31
   PubMed Web of Science ®Google Scholar
• Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006;6(3):514-22
   PubMed Web of Science ®Google Scholar
• Lo A, Egidi MF, Gaber LW, et al. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 2004;18(1):53-61
   PubMedGoogle Scholar
• Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant 2014;14(Suppl 1):11-44
   PubMed Web of Science ®Google Scholar
• Webster AC, Pankhurst T, Rinaldi F, et al. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation 2006;81(7):953-65
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Friend PJ, Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 2009;87(7):1092-5
   PubMed Web of Science ®Google Scholar
• van den Hoogen MW, Hesselink DA, van Son WJ, et al. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am J Transplant 2013;13(1):192-6
   PubMedGoogle Scholar
• Thibaudin D, Alamartine E, de Filippis JP, et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998;13(3):711-15
   PubMedGoogle Scholar
• Mourad G, Morelon E, Noel C, et al. The role of Thymoglobulin induction in kidney transplantation: an update. Clin Transplant 2012;26(5):E450-64
   PubMed Web of Science ®Google Scholar
• Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011;11(7):1359-67
   PubMed Web of Science ®Google Scholar
• Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 2012;25(6):623-32
   PubMedGoogle Scholar
• Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014;14(2):255-71
   PubMed Web of Science ®Google Scholar
• Guttmann RD, Caudrelier P, Alberici G, Touraine JL. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997;29(7A):24S-6S
   Web of Science ®Google Scholar
• Mathieu C, Renoult E, De March A. Serum anti-rabbit and anti-horse IgG, IgA, IgM in kidney transplant recipients. Nephrol Dial Transplant 1997;12:2133
   PubMedGoogle Scholar
• Cantarovich D, Giral-Classe M, Hourmant M. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000;69:1505
   PubMed Web of Science ®Google Scholar
• Cantarovich D, Giral-Classe M, Hourmant M. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporine after renal transplantation. Nephrol Dial Transplant 2000;15:1673
   PubMedGoogle Scholar
• Cantarovich D, Karam G, Giral-Classe M. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998;54:1351
   PubMed Web of Science ®Google Scholar
• Buchler M, Hurault de Ligny B, Madec C. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation. Clin Transplant 2003;17:539
   PubMed Web of Science ®Google Scholar
• Charpentier B, Rostaing L, Berhtous F. A three-arm study comparing immudiate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003;75:844
   PubMed Web of Science ®Google Scholar
• Mourad G, Garrigue V, Squifflet J. Induction versus no induction in renal transplant recipients with tacrolimus based immunosuppression. Transplantation 2001;72:1050
   PubMed Web of Science ®Google Scholar
• Boothpur R, Hardinger KL, Skelton RM, et al. Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure. Am J Kidney Dis 2010;55(1):141-3
   PubMed Web of Science ®Google Scholar
• Tanriover B, Chuang P, Fishbach B. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation 2005;80:279-81
   PubMed Web of Science ®Google Scholar
• Book B, Pescovits M, Agarwal A. In vitro monitoring of in vivo development of human anti-thymoglobulin antibodies by ELISA. Transplant Proc 2006;38:2869-71
   PubMed Web of Science ®Google Scholar
• Lundquist A, Chari R, Wood J. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007;13:647-50
   PubMedGoogle Scholar
• Leunissen K, Kootstra G, Mooy J. Plasmapheresis and RATG-induced serum sickness. Clin Transplant 1988;2:5-8
   Google Scholar
• Bailey T, Powderly W, Storch G. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection porphylaxis. Am J Kidney Dis 1993;21:196-201
   PubMedGoogle Scholar
• Hibberd P, Tolkoff-Rubin N, Cosimi A. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53:68-72
   PubMed Web of Science ®Google Scholar
• Jagose J, Bailey R, KL L. OKT3 for the treatment of steroid-resistant acute renal allograft rejection. Nephron 1997;77:298-303
   PubMedGoogle Scholar
• OH CS, Stratta RJ, Fox BC. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988;45:68-73
   PubMed Web of Science ®Google Scholar
• Ozaki K, Pestana J, Granato C. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies. Transpl Infect Dis 2004;6:63-8
   PubMedGoogle Scholar
• Ducloux D, Kazory A, Challier B. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004;77:1029-33
   PubMed Web of Science ®Google Scholar
• Clesca P, Dirlando M, Park S. Thymoglobulin and rate of infectious complications after transplantation. Transplant Proc 2007;39:463-4
   PubMedGoogle Scholar
• Arichi N, Kishikawa H, Nishimura K. Malignancy following kidney transplantation. Transplant Proc 2008;40:2400-2
   PubMedGoogle Scholar
• Cherikh W, Kauffman H, McBride M. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289-93
   PubMed Web of Science ®Google Scholar
• Bustami R, Ojo A, Wolfe R. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4:87-93
   PubMed Web of Science ®Google Scholar
• Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7(11):2619-25
   PubMed Web of Science ®Google Scholar